LKT Laboratories, Inc.

# RAF265

*Phone:* 888-558-5227
651-644-8424
*Fax:* 888-558-7329
*Email:* getinfo@lktlabs.com
*Web:* lktlabs.com

## Product Information

**Product ID** R0020
**CAS No.** 927880-90-8
**Chemical Name** 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine
**Synonym**



**Formula** $C_{24}H_{16}F_6N_6O$
**Formula Wt.** 518.4
**Melting Point**
**Purity** ≥98%
**Solubility** DMSO 100 mg/mL (192.89 mM)
Ethanol 33 mg/mL (63.65 mM)
Water Insoluble
**Store Temp** -20˚C
**Ship Temp** Ambient

***Bulk quanitites available upon request***

| Product ID | Size |
|---|---|
| R0020 | 1 mg |
| R0020 | 5 mg |

**Description** RAF265 is an orally bioavailable anticancer chemotherapeutic compound that inhibits primarily WT B-Raf, mutant (V600E) B-Raf, and VEGFR2, but is also active against c-Raf, PDGFR, CSF-1R, RET, c-Kit, Src, and STE20. This compound is in clinical trials as a treatment for unresectable or metastatic melanoma. Inhibition of B-Raf by RAF265 attenuates downstream ERK and RET signaling, preventing tumor cell proliferation. Raf265-induced alterations in ERK signaling also decreases expression of c-fos and NFATc1, inhibiting in vitro differentiation of PBMCs to osteoclasts and inhibiting osteoclast resorptive capacity, therefore inhibiting osteoclastogenesis.

**References**

Garcia-Gomez A, Ocio EM, Pandiella A, et al. RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5. d PMID: 22773056.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

Su Y, Vilgelm AE, Kelley MC, et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res. 2012 Apr 15;18(8):2184-98. Erratum in: Clin Cancer Res. 2012 Aug 15;18(16):4475. PMID: 22351689.